Company: BIAF
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024163
Chunk: 16

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 16
---
2025  
    2024  
    2025  
    2024 
  
    Net revenue: 

    Diagnostic R&D 
    $—  
    $4,038  
    $—  
    $6,923 
  
    Laboratory services 1 
     1,269,483  
     2,393,614  
     3,123,080  
     4,797,120 
  
    Total net revenue 
     1,269,483  
     2,397,652  
     3,123,080  
     4,804,043 

    Operating expenses: 

    Diagnostic R&D 
     (440,651) 
     (453,895) 
     (946,390) 
     (896,494)
  
    Laboratory services 
     (1,646,471) 
     (2,535,285) 
     (3,914,127) 
     (5,272,284)
  
    General corporate activities 
     (1,697,921) 
     (1,496,270) 
     (3,405,262) 
     (2,668,293)
  
    Total operating loss 
     (2,515,560) 
     (2,087,798) 
     (5,142,699) 
     (4,033,028)

    Non-operating income (expense), net 
     (1,516,243) 
     (17,062) 
     (1,540,826) 
     (29,975)
  
    Net loss before income tax expense 
     (4,031,803) 
     (2,104,860) 
     (6,683,525) 
     (4,063,003)
  
    Income tax expense 
     (28,984) 
     (5,419) 
     (37,679) 
     (9,091)
  
    Net loss 
    $(4,060,787) 
    $(2,110,279) 
    $(6,721,204) 
    $(4,072,094)

    1
    The
    majority of the decrease versus the prior year is primarily due to discontinuing certain unprofitable